Five-Minute Interview

Q Core CEO Remains Techie at Heart


Posted by Camilla Andersson on January 4, 2012

The Five Minute Interview series offers personal perspectives on the diverse and dynamic medical technology sector. Here, we talk to Boaz Eitan, PhD, CEO and Chairman of infusion pump maker Q Core.


Boaz Eitan, PhD, CEO and Chairman of infusion pump maker Q Core.

Q What is the first thing you do when you get to the office?
A
I take a walk through the manufacturing facility of our Multi-Therapy infusion pumps. I love the beat of the test machines and the packaging noises at the end of the line. I am very proud of the pace. Orders have picked up way faster than expected and our operators are working full shifts, the testing machines are in full speed and the rhythm is fascinating.

Q If I were not talking to you right now, what would you be doing?
A
Sitting in the lab. I spend a lot of lab time with each of our innovation groups, and that’s where you are most likely to find me. While managing and orchestrating business deals takes much of my time, my biggest passion (and strength) is technology. I am always trying to get to the lab to improve yields and find ways to reduce cost through innovation. We are constantly working to add features to our existing product portfolio as well as to develop innovative new products. 

Q How did you get in the industry?
A
After 30 years in semiconductors—I founded Saifun Semiconductor, took it to an IPO in the United States and then sold it to Spansion—the opportunity to purchase Q Core and move into the medical device space was extremely exciting. Semiconductors is a world of massive corporations with extremely expensive manufacturing fabs; in the infusion pump arena, there are inherent advantages to being a small, adaptable organisation.

Q What is the best thing about your work?
A
I love turning an idea into an R&D project, moving it to production and seeing it succeed in the marketplace.

Q Will your job be any different five years from now?
A
It had better be or I will not be happy. Growth almost always requires change, and as new fields and products develop, my staff and I will face new challenges.

Q What’s so great about your company’s technology? 
A
Q Core’s highly reliable and robust mechanics are controlled by flexible software, helping us to create a single platform that enables Multi Therapy treatments. These technologies give our infusion pumps high accuracy, an extremely long battery life and many other performance advantages. More importantly, they give care providers and nonprofessionals a very easy-to-use product that requires minimal training time. For purchasers, the technology makes the product extremely cost effective when its entire life cycle is taken into account.

Q What do you think is the most important medical device invention ever?
A
The x-ray brought clarity and certainty to things that could only be imagined before, and it integrated the amazing world of physics into the medical field.

Q What is the most exciting development on the horizon?
A
Technologically in our field, I would look at oncology treatments. New equipment incorporating closed systems prevents air from getting into the infusion line, which is a problem for patients and caregivers. With conventional systems, the administration set must be disconnected from the patient to remove air, which leads to the evaporation of toxins and expensive drug spillage. A closed system not only prevents toxins from contaminating the treatment area but also avoids wasting expensive drugs. Furthermore, eliminating the need to disconnect the set from the patient is safer for individuals who already have a weak immune system.

Boaz Eitan, PhD, is CEO and Chairman of Q Core, a company focused on the medical infusion pump market. Based on proprietary technology, the infusion pump systems and disposables improve drug-delivery safety. The company is located at 14 Hamefalsim St., Petach Tikva 49130, Israel. Eitan can be reached by phone, +972 73 2388 888, or via e-mail, info@qcore.com. www.qcore.com.



Find more content on:
No votes yet


Login or register to post comments